Cancer-drug makers keep winning while AI stocks sink — rotate into pharma

Verdict: The rotation story is real, but Bayer's Q2 numbers and an RSI at 80 say wait for the pullback

Over the next three to six months, the healthcare-rotation thesis is plausible but not yet ready to chase: Bayer raised its annual profit outlook on strong drug demand (per Bloomberg, November 3, 2026) and Genmab's cancer-drug wins doubled its shares (per CNBC), yet Bayer's most recent quarter showed revenue down 18.9% to €10.9B and net income down 92% to €219M, with operating margin at just 7.6%. The strongest evidence for the idea is the clean momentum confirmation — XLV sits within 0.15% of its range high with a strong trend gauge, and Bayer is back to positive quarterly earnings after a €3.76B loss in Q4 2025. The strongest counter is that both legs are stretched at the same time: BAYRY's 14-day momentum gauge reads 80.4 and XLV's reads 75.9, meaning the strategy would buy into a condition its own overbought rule flags as an exit, on top of a leveraged balance sheet (debt-to-equity of 1.40 at fiscal year-end 2025 and a current ratio of just 1.01). We would reassess on a pullback that holds the $13.63 support level, or a Q3 report showing pharma margins recovering. Note that the strategy's parameter-robustness check never completed, so the historical results rest on one fixed configuration, and Genmab had no usable price history in our data — its diversification role is unmeasured.

Trade now

As of the Nov 3 observation, the strategy's entry conditions are currently met on both Bayer (BAYRY) and the healthcare sector ETF (XLV), so the mechanical trigger side of the setup is live. But live does not mean attractive at any price: BAYRY closed at $13.95 with a 14-day RSI of 80.4 — a momentum gauge above 70 that typically flags stretched conditions — and the strategy's own overbought exit rule (RSI above 70) is already satisfied. In plain terms, the system would be buying into a condition it also treats as an exit signal. On the 60-month backtest this rule set returned 9.1% across 165 trades with a 42.4% win rate and a worst peak-to-trough decline of about 10.3%; the last 24 months were better (14.3% return, 48.8% win rate, 5% max drawdown). Exits were filled on daily bars rather than intraday, so those exit-quality numbers are coarse. Two caveats shape the decision. First, no robust parameter setup was established — the sensitivity evaluation ran out of its time budget before producing a recommendation, so there is no evidence the chosen thresholds are stable rather than a lucky fit. Second, the 12-month backtest window failed to run at all due to a data-loading error, so the most recent-year regime is untested; and the recent Bayer fundamentals cut the other way — Q2 revenue fell 18.9% from the prior quarter to €10.87B and net income dropped 92% to €219M, even though the idea argues the raised profit forecast and pharma rotation thesis outweigh that. Our read: the business-thesis case (defensive rotation into pharma after Genmab's wins and Bayer's guidance raise) is plausible but already substantially priced in, with RSI readings above 75 on both legs. The concrete wait is a pullback entry, not a fresh chase: the strategy's own Fibonacci-based entry allows buying when price dips to the 38.2% retracement and closes back above it, and the nearest support sits at $13.63 versus resistance at $13.99. A patient entry near support keeps the fixed-risk sizing (2% risk per trade, hard stops at −2% and +4% profit-taking) meaningful. The downside that matters is a quick reversal through the $13.63 support that flips the short-term moving-average trend — the same conditions the strategy uses to exit. ### Technical details Entry rules (observed Nov 3, ~13:13 UTC, daily timeframe): BAYRY at $13.95, EMA(9) $13.18 above EMA(21) $12.98 (met), RSI(14) 80.4 above 50 (met), ADX(14) 22.1 above 20 (met — a trend-strength gauge above 20 means a directional trend exists). Every one of the four conditions is also met on XLV at $184.6 (RSI 75.9, ADX 31.7, EMA(9) $181.32 above EMA(21) $177.62). Distance-to-trigger: zero — the entry setup is already fully satisfied. Fibonacci entry (38.2% retracement dip-and-reclaim) is the pullback alternative; the retracement level itself is not supplied. Exits: overbought RSI above 70 (currently met on both), take-profit at resistance rank 2 or +4%, stop-loss below support rank 2, the 78.6% Fibonacci level, or −2% on the position. Position sizing caps any single position at 25% of the book.

Fresh earnings upgrades and a working rotation signal give the bull case real footing

The fundamental news matches the bullish rotation thesis: Bayer raised its profit outlook on strong drug demand, Genmab just doubled on a cancer-drug win, and the strategy's realized backtest shows the momentum approach capturing the healthcare uptrend with defined, small per-trade risk. ### Bayer just raised guidance on pharma demand Per the Bloomberg report of November 3, 2026, Bayer raised its annual profit outlook helped by strong demand for drugs. The numbers corroborate a demand inflection: Q2 2026 revenue of €10.9B and a return to quarterly net income of €219M in Q2 after a €3.76B loss in Q4 2025, with Q1 2026 net income of €2.76B. For a value-profile idea, a guidance raise supported by volume — not cost cuts alone — is the kind of catalyst that re-rates a depressed stock. ### Genmab is the clean-growth leg of the pair Per CNBC on November 3, 2026, Genmab's cancer-drug wins doubled its shares. The filings support quality behind the headline: Q2 2026 revenue of $1.16B (up 28.9% quarter over quarter), net margin jumping from 5.9% to 26.2%, operating margin at 35.2%, and a gross margin above 92%. Genmab carries far less balance-sheet baggage than Bayer (debt-to-equity of 0.89 in Q2 2026 versus Bayer's unavailable latest reading but 1.40 at FY 2025), so the two names diversify the idea across a turnaround story and a pure-growth biotech. ### The realized backtest shows the trend filter works on this pair The 60-month daily backtest completed 165 trades with a 42.4% win rate and a +9.1% total return, with a maximum drawdown of 10.3% over that window. The best-performing window, the last 24 months, returned +14.3% on 80 trades with a 48.8% win rate and only a 5.0% maximum drawdown — meaning recent healthcare momentum is exactly the regime this EMA/RSI/ADX setup was built for. The position sizing (fixed risk at 2% per trade, 25% maximum position) caps the damage of any single failed signal, which is why the worst historical loss stayed near 10% over five years rather than compounding. ### Sector insulation from the current macro scares The idea argues healthcare avoids the AI-spending and China exposures frightening the market. The XLV look-through supports this: the fund is 100% healthcare by sector, with look-through constituents showing 16.7% year-over-year revenue growth and an 18.7% net margin — earnings that exist independent of the tech narrative. If capital rotates out of tech as the thesis…

Scores

• Conviction score breakdown: 44
• Thesis support: 62
• Trade readiness: 38
• Risk quality: 45
• Backtest evidence: 42
• Fundamentals trend: 35

Watch items

• BAYRY — RSI (14)
• BAYRY — Close vs nearest support
• BAYRY — Close vs nearest resistance
• BAYRY — EMA (9) vs EMA (21)
• XLV — RSI (14)